PAIN
Volume 139, Issue 3 , Pages 494-497 , 31 October 2008

Conflicts of interest in pain medicine: Practice patterns and relationships with industry

  • Jerome Schofferman

      Affiliations

    • SpineCare Medical Group, San Francisco Spine Institute, Daly City, CA, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • John Banja

      Affiliations

    • Center for Ethics, Emory University, Atlanta, GA, USA

Received 22 July 2008 ,Accepted 27 August 2008.

References 

  1. Association of American Medical Colleges. “Report of the AAMC Task Force on Industry Funding of Medical Education to the AAMC Executive Council.” For consideration, June 18–19, 2008. Available from: https://services.aamc.org/Publications/showfile.cfm?file=version114.pdf&prd_id=232.
  2. Association of American Medical Colleges. “A report of the AAMC-AAU Advisory committee on financial conflicts of interest in human subjects research. Protecting patients, preserving integrity, advancing health: accelerating the implementation of COI policies in human subjects research.” February 2008. Available from: https://services.aamc.org/Publications/showfile.cfm?file=version107.pdf&prd_id=220&prv_id=268&pdf_id=107.
  3. Association of American Medical Colleges. The Scientific Basis of Influence and Reciprocity. A Symposium. June 12, 2007. Available from: https://services.aamc.org/Publications/index.cfm?fuseaction=Product.displayForm&prd_id=215&prv_id=262.
  4. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998;279:1566–1570
  5. Bekelman J, Yan L, Gross C. Scope and impact of financial conflicts of interest in biomedical research. JAMA. 2003;289:454–465
  6. Brennan T, Rothman D, Blank L, Blumenthal D, Chimonas S, Cohen J, et al. Health industry practices that create conflicts of interest. A policy proposal for academic medical centers. JAMA. 2006;295:429–433
  7. Brody H Hooked. Ethics, the medical profession, and the pharmaceutical industry. Lanham, MD: Rowman & Littlefield; 2007;p. 200–14
  8. Brody H Hooked. Ethics, the medical profession, and the pharmaceutical industry. Lanham, MD: Rowman & Littlefield; 2007;p. 287–98
  9. Cain D, Detsky AS. Everyone’s a little bit biased (even physicians). JAMA. 2008;299:2893–2895
  10. Cain D, Loewenstein G, Moore D. Coming clean but playing dirtier. The shortcomings of disclosure as a solution to conflicts of interest. In:  Moore D,  Cain D,  Loewenstein G,  Bazerman M editor. Conflicts of interest. Challenges and solutions in business, law, medicine, and public policy. New York, NY: Cambridge University Press; 2005;p. 104–125
  11. Campbell E, Weissman J, Vogeli C, Clarridge B, Abraham M, Marder J, et al. Financial relationships between institutional review board members and industry. N Engl Med. 2006;355:2321–2329
  12. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252–255
  13. DeAngelis C, Fontanarosa P. Impugning the integrity of medical science. The adverse effects of industry influence. JAMA. 2008;299:1833–1835
  14. Erde EL. Conflicts of interest in medicine: a philosophical and ethical morphology. In:  Speece RG,  Shimm DS,  Buchanan AE editor. Conflicts of interest in clinical practice and research. New York, NY: Oxford University Press; 1996;p. 12–41
  15. Hensley S. Remedial lessons: when doctors go to class, industries often foot the bill. Wall Street J. 2002;A1
  16. Katz D, Caplan A, Merz J. All gifts large and small. Toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3(3):39–46
  17. Moffatt B, Elliott C. Ghost marketing. Pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med. 2007;50:18–31
  18. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285:2009–2012
  19. RxPromoROI. The RAPP study: executive summary. http://www.rxpromoroi.org/rapp/exec_sum.html.
  20. Schofferman J. Interventional pain medicine: financial success and ethical practice: an oxymoron?. Pain Med. 2006;7:457–460
  21. Shah R, Albert T, Bruegel-Sanchez V, Vaccaro A, Hilibrand A, Grauer J. Industry support and correlation with study outcome for papers published in Spine. Spine 2005;30:1099.
  22. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29:109–113
  23. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 2007. http://medicine.plosjournals.org/archive/1549-1676/4/9/pdf/10.1371_journal.pmed.0040286-L.pdf.
  24. Steinbrook R. Financial support of continuing medical education. JAMA. 2008;299:1060–1062
  25. Steinbrook R. Public registration of clinical trials. N Engl J Med. 2004;351:315–317
  26. Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med. 2005;352:2160–2162
  27. Rothman D. Academic medical centers and financial conflicts of interest. JAMA. 2008;299:695–697
  28. Thompson D. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573–576
  29. Tonelli M. Conflict of interest in clinical practice. Chest. 2007;132:664–670
  30. Turner E, Matthews A, Linardatos E, Tell R, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl Med. 2008;358:252–260
  31. Weiner B, Levi B. The profit motive and spine surgery. Spine. 2004;29:2588–2591
  32. Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain. 2006;121:207–218

PII: S0304-3959(08)00501-0

doi: 10.1016/j.pain.2008.08.016

PAIN
Volume 139, Issue 3 , Pages 494-497 , 31 October 2008

Article Tools